vs
Rollins, Inc.（ROL）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Rollins, Inc.的季度营收约是Revvity的1.2倍（$906.4M vs $772.1M），Revvity净利率更高（12.7% vs 11.9%，领先0.8%），Rollins, Inc.同比增速更快（10.2% vs 5.9%），Revvity自由现金流更多（$161.8M vs $111.2M），过去两年Revvity的营收复合增速更高（9.0% vs 0.8%）
Rollins, Inc.是北美知名虫害防治服务商，面向住宅及商业客户提供专业防控服务。公司依托Orkin、HomeTeam Pest Defense等多家全资子公司布局全球业务，覆盖北美、英国等市场，在民用及商用虫害治理领域具备深厚的行业积累与品牌优势。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ROL vs RVTY — 直观对比
营收规模更大
ROL
是对方的1.2倍
$772.1M
营收增速更快
ROL
高出4.4%
5.9%
净利率更高
RVTY
高出0.8%
11.9%
自由现金流更多
RVTY
多$50.6M
$111.2M
两年增速更快
RVTY
近两年复合增速
0.8%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $906.4M | $772.1M |
| 净利润 | $107.8M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 16.1% | 14.5% |
| 净利率 | 11.9% | 12.7% |
| 营收同比 | 10.2% | 5.9% |
| 净利润同比 | 2.5% | 3.9% |
| 每股收益（稀释后） | $0.22 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ROLRVTY
| Q1 26 | $906.4M | — | ||
| Q4 25 | $912.9M | $772.1M | ||
| Q3 25 | $1.0B | $698.9M | ||
| Q2 25 | $999.5M | $720.3M | ||
| Q1 25 | $822.5M | $664.8M | ||
| Q4 24 | $832.2M | $729.4M | ||
| Q3 24 | $916.3M | $684.0M | ||
| Q2 24 | $891.9M | $691.7M |
净利润ROLRVTY
| Q1 26 | $107.8M | — | ||
| Q4 25 | $116.4M | $98.4M | ||
| Q3 25 | $163.5M | $46.7M | ||
| Q2 25 | $141.5M | $53.9M | ||
| Q1 25 | $105.2M | $42.2M | ||
| Q4 24 | $105.7M | $94.6M | ||
| Q3 24 | $136.9M | $94.4M | ||
| Q2 24 | $129.4M | $55.4M |
毛利率ROLRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% |
营业利润率ROLRVTY
| Q1 26 | 16.1% | — | ||
| Q4 25 | 17.5% | 14.5% | ||
| Q3 25 | 21.9% | 11.7% | ||
| Q2 25 | 19.8% | 12.6% | ||
| Q1 25 | 17.3% | 10.9% | ||
| Q4 24 | 18.1% | 16.3% | ||
| Q3 24 | 20.9% | 14.3% | ||
| Q2 24 | 20.4% | 12.4% |
净利率ROLRVTY
| Q1 26 | 11.9% | — | ||
| Q4 25 | 12.8% | 12.7% | ||
| Q3 25 | 15.9% | 6.7% | ||
| Q2 25 | 14.2% | 7.5% | ||
| Q1 25 | 12.8% | 6.4% | ||
| Q4 24 | 12.7% | 13.0% | ||
| Q3 24 | 14.9% | 13.8% | ||
| Q2 24 | 14.5% | 8.0% |
每股收益（稀释后）ROLRVTY
| Q1 26 | $0.22 | — | ||
| Q4 25 | $0.24 | $0.86 | ||
| Q3 25 | $0.34 | $0.40 | ||
| Q2 25 | $0.29 | $0.46 | ||
| Q1 25 | $0.22 | $0.35 | ||
| Q4 24 | $0.22 | $0.77 | ||
| Q3 24 | $0.28 | $0.77 | ||
| Q2 24 | $0.27 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $116.5M | $919.9M |
| 总债务越低越好 | $650.6M | — |
| 股东权益账面价值 | $1.4B | $7.3B |
| 总资产 | $3.2B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.47× | — |
8季度趋势，按日历期对齐
现金及短期投资ROLRVTY
| Q1 26 | $116.5M | — | ||
| Q4 25 | $100.0M | $919.9M | ||
| Q3 25 | $127.4M | $931.4M | ||
| Q2 25 | $123.0M | $991.8M | ||
| Q1 25 | $201.2M | $1.1B | ||
| Q4 24 | $89.6M | $1.2B | ||
| Q3 24 | $95.3M | $1.2B | ||
| Q2 24 | $106.7M | $2.0B |
总债务ROLRVTY
| Q1 26 | $650.6M | — | ||
| Q4 25 | $486.1M | — | ||
| Q3 25 | $485.7M | — | ||
| Q2 25 | $485.3M | — | ||
| Q1 25 | $485.5M | — | ||
| Q4 24 | $395.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益ROLRVTY
| Q1 26 | $1.4B | — | ||
| Q4 25 | $1.4B | $7.3B | ||
| Q3 25 | $1.5B | $7.4B | ||
| Q2 25 | $1.4B | $7.6B | ||
| Q1 25 | $1.4B | $7.6B | ||
| Q4 24 | $1.3B | $7.7B | ||
| Q3 24 | $1.3B | $7.9B | ||
| Q2 24 | $1.2B | $7.9B |
总资产ROLRVTY
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.1B | $12.2B | ||
| Q3 25 | $3.2B | $12.1B | ||
| Q2 25 | $3.2B | $12.4B | ||
| Q1 25 | $2.9B | $12.4B | ||
| Q4 24 | $2.8B | $12.4B | ||
| Q3 24 | $2.8B | $12.8B | ||
| Q2 24 | $2.8B | $13.4B |
负债/权益比ROLRVTY
| Q1 26 | 0.47× | — | ||
| Q4 25 | 0.35× | — | ||
| Q3 25 | 0.32× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.36× | — | ||
| Q4 24 | 0.30× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $118.4M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $111.2M | $161.8M |
| 自由现金流率自由现金流/营收 | 12.3% | 21.0% |
| 资本支出强度资本支出/营收 | 0.8% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.10× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $621.1M | $509.4M |
8季度趋势，按日历期对齐
经营现金流ROLRVTY
| Q1 26 | $118.4M | — | ||
| Q4 25 | $164.7M | $182.0M | ||
| Q3 25 | $191.3M | $138.5M | ||
| Q2 25 | $175.1M | $134.3M | ||
| Q1 25 | $146.9M | $128.2M | ||
| Q4 24 | $188.2M | $174.2M | ||
| Q3 24 | $146.9M | $147.9M | ||
| Q2 24 | $145.1M | $158.6M |
自由现金流ROLRVTY
| Q1 26 | $111.2M | — | ||
| Q4 25 | $159.0M | $161.8M | ||
| Q3 25 | $182.8M | $120.0M | ||
| Q2 25 | $168.0M | $115.5M | ||
| Q1 25 | $140.1M | $112.2M | ||
| Q4 24 | $184.0M | $149.8M | ||
| Q3 24 | $139.4M | $125.6M | ||
| Q2 24 | $136.4M | $136.6M |
自由现金流率ROLRVTY
| Q1 26 | 12.3% | — | ||
| Q4 25 | 17.4% | 21.0% | ||
| Q3 25 | 17.8% | 17.2% | ||
| Q2 25 | 16.8% | 16.0% | ||
| Q1 25 | 17.0% | 16.9% | ||
| Q4 24 | 22.1% | 20.5% | ||
| Q3 24 | 15.2% | 18.4% | ||
| Q2 24 | 15.3% | 19.7% |
资本支出强度ROLRVTY
| Q1 26 | 0.8% | — | ||
| Q4 25 | 0.6% | 2.6% | ||
| Q3 25 | 0.8% | 2.6% | ||
| Q2 25 | 0.7% | 2.6% | ||
| Q1 25 | 0.8% | 2.4% | ||
| Q4 24 | 0.5% | 3.4% | ||
| Q3 24 | 0.8% | 3.3% | ||
| Q2 24 | 1.0% | 3.2% |
现金转化率ROLRVTY
| Q1 26 | 1.10× | — | ||
| Q4 25 | 1.41× | 1.85× | ||
| Q3 25 | 1.17× | 2.97× | ||
| Q2 25 | 1.24× | 2.49× | ||
| Q1 25 | 1.40× | 3.03× | ||
| Q4 24 | 1.78× | 1.84× | ||
| Q3 24 | 1.07× | 1.57× | ||
| Q2 24 | 1.12× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ROL
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
